NCT05182567进行中（未招募）1 期
Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Given as a Booster to Those Previously Vaccinated Against SARS-CoV-2
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 69
- 试验地点
- 2
- 主要终点
- Incidence of adverse events
研究概览
简要总结
Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against SARS-CoV-2
详细描述
This Phase I, randomized, placebo-controlled study will assess the safety, tolerability, and immunogenicity of GLS-5310 DNA vaccine administered intradermally (ID) with or without concomitant intranasal (IN) administration given as a heterologous booster dose to those previously vaccinated against SARS-CoV-2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 to 65 years of age
- •Able to provide informed consent
- •Able and willing to comply with study procedures and agree to refrain from obtaining a booster vaccination with a non-study vaccine through to the 1 month post-boost vaccination visit
- •For women of childbearing potential, able and willing to use an approved form of pregnancy prevention for at least 4 weeks from study drug administration
- •Completion of a prior vaccination series with either the BNT162b2, mRNA-1273, or Ad26.CoV.S vaccines, with or without subsequent booster vaccination, with most recent vaccination at least 6 months prior to study entry
排除标准
- •Persons with symptoms in the past 2 weeks consistent with possible acute SARS-CoV-2 infection (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
- •Persons with a diagnosis of type 2 diabetes mellitus
- •Persons with a diagnosis of chronic kidney disease
- •Persons with a diagnosis of chronic obstructive pulmonary disease (COPD)
- •Persons with a diagnosis of heart conditions to include heart failure, coronary artery disease, prior heart attack, cardiomyopathy
- •Sickle cell disease
- •Current or planned pregnancy during the study
- •Currently breastfeeding
- •Administration of an investigational agent within 90 days of the GLS-5310 booster dose
- •Administration of a vaccine within 2 weeks prior to the GLS-5310 booster dose
- •Administration of immune globulin within 6 months of enrollment
- •Administration of an anti-TNFα inhibitor such as infliximab, adalimumab, etanercept, or anti-CD20 monoclonal antibody rituximab within 6 months from enrollment
- •Current daily treatment of systemic corticosteroids of 20 mg of prednisone or greater; or the equivalent dose of other systemic corticosteroids
- •Treatment within the four weeks prior to enrollment with any drug intended for the prophylaxis or treatment of COVID-19
- •Any prior treatment with an anti-SARS-CoV-2 monoclonal antibody or immune serum
- •Prior treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or anti-JAK inhibitor (see Appendix B exclusionary period for specific drugs)
- •History of malignancy
- •History of transplantation (any organ or bone marrow)
- •Current or planned chemotherapy treatment for hematologic or solid tumor during study period
- •History of other congenital or acquired immunodeficiency, excluding those with HIV infection who are taking highly active antiretroviral therapy and who have documentation of undetectable serum viral load and who have a CD4 count > 200 cells/μL on two measures at least 3 months apart
- •Not willing to allow storage and future use of samples for coronavirus-related research and/or vaccine development
- •Prisoner or subjects who are compulsorily detained for treatment of a psychiatric illness
- •Any illness or condition that, in the opinion of the investigator, may affect the safety of the subject or the evaluation of a study endpoint
- •History of chronic rhinosinusitis
- •History of nasal septal defect or deviated nasal septum
- •History of cleft palate
- •History of nasal polyps
- •History of other disorders that, in the opinion of the investigator, may adversely affect administration of intranasal vaccine
研究组 & 干预措施
GLS-5310 ID + GeneDerm 65 kPa, 30 seconds
Experimental
GLS-5310 ID + GeneDerm administered at Visit 1
干预措施: GLS-5310 (Group 1) (Drug)
GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 IN
Experimental
GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
干预措施: GLS-5310 (Group 2) (Drug)
GLS-5310 ID + GeneDerm 65 kPa, 15 seconds
Experimental
GLS-5310 ID + GeneDerm administered at Visit 1
干预措施: GLS-5310 (Group 3) (Drug)
GLS-5310 ID + GeneDerm 80 kPa, 30 seconds
Experimental
GLS-5310 ID + GeneDerm administered at Visit 1
干预措施: GLS-5310 (Group 4) (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Through 48 weeks post vaccination
Solicited/unsolicited local and systemic AEs after vaccination
Determine antibody responses after a single dose of vaccine
时间窗: Through 48 weeks post vaccination
The fold change of SARS-CoV-2 Spike binding antibodies 1-month post-booster
次要结局
- Evaluation of positive response rate of T cell responses induced by GLS-5310 DNA vaccine(Through 48 weeks post vaccination)
- Evaluation of neutralizing antibody response induced by GLS-5310 relative to treatment arm(Through 48 weeks post vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)Covid19HealthyNCT05085639GeneOne Life Science, Inc.30
已完成
1 期
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)SARS-CoV-2NCT04673149GeneOne Life Science, Inc.171
已完成
1 期
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by ElectroporationMelanoma (Skin)Intraocular MelanomaNCT00471133Ichor Medical Systems Incorporated24
已完成
1 期
GLS-5700 in Dengue Virus-Naïve AdultsHealthyNCT02809443GeneOne Life Science, Inc.40
已完成
1 期
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy AdultsHIV InfectionsNCT00528489National Institute of Allergy and Infectious Diseases (NIAID)120